Amyloid Light Chain (AL) Amyloidosis is a condition where abnormal proteins called amyloids build up in organs and tissues. This study focuses on the safety of using a medicine called Daratumumab along with other treatments like Cyclophosphamide, Bortezomib, and Dexamethasone for people newly diagnosed with AL amyloidosis that affects the heart. The study is in two parts: one checks heart safety, and the other looks at how the medicine works in different racial groups.

Key Points:

• The study requires multiple visits and tests over several months.
• Participants can be compensated for their time and travel.
• There are possible risks like heart issues or side effects from the treatment.

Participants must meet certain health criteria, such as having heart involvement and not having previous treatments for AL amyloidosis. Both men and women must agree to certain birth control measures during the study. The study excludes those with severe nerve pain or certain other treatments. Understanding these criteria and potential risks is important before joining the study.